Patent: 10,450,613
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,450,613
Title: | EGFR/NEDD9/TGF-.beta. interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
Abstract: | Compositions and methods for the treatment and diagnosis of cancer are disclosed. |
Inventor(s): | Astsaturov; Igor (Philadelphia, PA), Golemis; Erica A. (Oreland, PA), Serebriiskii; Ilya G. (Rockledge, PA), Weiner; Louis M. (Washington, DC) |
Assignee: | Fox Chase Cancer Center (Philadelphia, PA) |
Application Number: | 15/171,663 |
Patent Claims: | see list of patent claims |
Details for Patent 10,450,613
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2027-11-09 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2027-11-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |